Navigation Links
BioMarin Announces First Quarter 2009 Financial Results
Date:4/30/2009

Net Product Revenue Increase of 25% Led by Naglazyme International Expansion

Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET)

NOVATO, Calif., April 30 /PRNewswire-FirstCall/ --


               Financial Highlights ($ in millions, except per share data)

    Item                                Q1 2009            Q1 2008 Comparison

    Total BioMarin Revenue              $74.0                23% increase
    Total Net Product Revenue           $71.9                25% increase
    Naglazyme Net Product Revenue       $39.4                42% increase
    Aldurazyme Net Sales by Genzyme     $36.8                No change
    Aldurazyme BioMarin Net Product
     Revenue                            $17.0                29% decrease*
    Kuvan Net Product Revenue           $15.5                168% increase
    GAAP Net Income (Loss)              $(13.2)              $1.7
    GAAP Net Income (Loss) per share    $(0.13) (basic       $0.02 (basic
                                                 and                and
                                                 diluted)           diluted)
    Non-GAAP Net Income                 $9.3                 $4.1
    Non-GAAP Net Income per share       $0.09 (basic         $0.04 (basic
                                               and                  and
                                               diluted)             diluted)

    * The decrease in Aldurazyme BioMarin net product revenue is
      attributable to the one-time transfer of a significant amount of
      Aldurazyme inventory in the first quarter of 2008 concurrent with the
      restructuring of the BioMarin/Genzyme LLC.  Total incremental product
      revenue totaled $9.5 million in the first quarter of 2008, compared to
      $2.5 million in the first quarter of 2009.  The number of patients on
      Aldurazyme therapy worldwide continues to increas
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
2. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
3. BioMarin to Present at the 4th Annual Citi Biotech Day
4. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
5. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
6. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
7. BioMarin to Present at the Piper Jaffray Healthcare Conference
8. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. BioMarin Announces Third Quarter 2008 Financial Results
11. BioMarin Corrects Information Included in Bloomberg Article
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Modeling Complex ... Biological Systems for Type 2 Diabetes, CAMBRIDGE, Mass., ... on identifying molecular mechanisms, networks and,biomarkers to better understand ... Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT ),a biopharmaceutical company ...
... CHURCH, Va., April 30 Computer Sciences,Corporation (NYSE: ... M. Wah, chief,medical officer and vice president of ... ranked number 10 in Modern Physician and Modern,Healthcare ... Physician,Executives, published in April. Readers from both magazines ...
... XI,AN, China, April 30 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical ... leading,developer and producer of plant extracts and ... and food production, today,announced that it will ... March 31 on Thursday, May 15, 2008, ...
Cached Biology Technology:Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award 2CSC's Dr. Robert M. Wah Makes Top 10 in 50 Most Powerful Physician Executives List 2
(Date:4/17/2014)... peppers. Information about archaeological remains of ancient chili peppers ... of words for chili peppers in ancient dialects helped ... the value of multi-proxy data analysis. Their results are ... presented in a special feature issue of the ... plant and animal domestication edited by Dolores Piperno, staff ...
(Date:4/17/2014)... April 16, 2014. Kessler Foundation has been named ... from the Department of Defense Spinal Cord Injury ... investigator for the randomized, double-blinded, controlled, multi-site clinical ... and muscle strength after spinal cord injury. Dr. ... Engineering Research at Kessler Foundation. Two additional sites ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2New state-of-the-art biotech and nanotech equipment for INRS 2
... have extraordinarily small balance organs, and scientists have long ... School of Medicine in St. Louis has contradicted a ... heads so vigorously that they had to have smaller, ... Working with a Midwestern zoo and a local ...
... be promising candidates for drug development has become easier ... medicinal chemistry group. Dr Jonathan Baell and Dr ... can be used to weed out those molecules likely ... chemical library for compounds that could be useful in ...
... ─ The National Institutes of Health has awarded Albert ... to combat childhood obesity in the Bronx. Working with ... Center for Einstein, a team of researchers will build ... the classroom to encourage physical activity and promote positive ...
Cached Biology News:Rodeo bull goes head-to-head with zoo dolphins in a study of balance 2Rodeo bull goes head-to-head with zoo dolphins in a study of balance 3Compound screening for drug development made simpler 2Einstein-Montefiore research tackles childhood obesity in the Bronx 2Einstein-Montefiore research tackles childhood obesity in the Bronx 3